Pfizer (PFE) concluded the recent trading session at $25.35, signifying a -1.17% move from its prior day's close.

Pfizer (NYSE: PFE) was on top of the world when it came to earnings and stock price performance. This was in early pandemic ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer, in partnership with Bristol Myers Squibb, has launched a direct-to-patient sales strategy for Eliquis®, aiming to ...

The purpose of investing in stocks is to make money, not lose it. So selling shares at a loss can be very upsetting. In this ...

Pfizer has caught investors’ eyes recently, outperforming its peers slightly but facing modest growth prospects ahead.

The completion of this study may positively influence Pfizer’s stock performance by demonstrating the effectiveness and safety of INLYTA® in real-world settings, potentially boosting investor ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Study Design: This interventional study is randomized and follows a parallel assignment model. It is double-blind, meaning neither participants nor the care providers, investigators, or outcome ...

Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an ...

AbbVie ABBV has been expanding its oncology portfolio over the past few years. While the company was originally focused on ...